|
|
 |
|
Viewing report
|
|
|
|
Disruption or Advantage? Update on Companion Diagnostics
Decision Resources, Inc., Sep 2009, Pages: 25
Some naysayers disagree, but we regard companion diagnostics as a win-win scenario for all stakeholders. Companion diagnostics combines drug and diagnostic test development. The potential for efficient drug development is huge because companion diagnostics can be used to predict drug response and treatment efficacy—therefore, companion diagnostics are also the perfect means to fulfilment of the promise of personalized medicine. But the advantages of companion diagnostics are only one side of the equation: they are also seen as disruptors of the pharmaceutical market that could restrict the size of treatable populations. Bringing the differing viewpoints together to form a unified idea of what companion diagnostics really mean to the industry is a challenge, but one that companies must heed because companion diagnostics are making their mark—like it or not.
Questions Answered in This Report:
- Regulatory and payer decisions on certain types of testing are increasingly influencing physician, patient, and industry perspectives. For instance, how has the FDA’s recent decision to alter the Vectibix and Erbitux labels affected industry dynamics?
- Companies that have developed companion diagnostics are viewed as valuable acquisition targets. Which companies are attracting potential buyers? What is the perceived impact of these acquisitions on the overall strategies of pharmaceutical companies?
- The availability of companion diagnostics in oncology is greater than in other therapy areas. Why is oncology such an attractive area for growth in personalized medicine? In what other areas is development of personalized medicine growing?
Scope:
Stakeholder analysis: Pharmaceutical companies, diagnostics companies, payers, regulatory agencies, physicians, and patients.
Recent trends and decisions: Regulating KRAS mutation tests, identification of genetic markers of response to Vanda’s Fanapt (iloperidone), reimbursement for warfarin testing, partnering and deal making in companion diagnostics.
Indications: Non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer, heart failure, arthritis, depression, chronic myelogenous leukemia (CML).
Company profiles: Pharmaceutical companies—Wyeth, Vanda Pharmaceuticals, Roche, Pfizer, Novartis, Johnson & Johnson, Eli Lilly, ARCA BioPharma, Amgen, and Abbott. Diagnostics companies—LabCorp, DxS, Dako, and Clinical Data.
Outlook: Spectrum Expert Commentary on future growth, therapeutic area emphasis, the promise of personalized medicine.
Customers who bought this item also bought
Companion Diagnostics - Global Strategic Business Report
The Landscape of Companion Diagnostics: Challenges, Opportunities, and Future Trends
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Novel Approaches to Developing Predictive Diagnostics
Enabling Oncology Diagnostics: Predictive Biomarkers Based on Genes, Proteins, and Pathways
Biomarker and Diagnostic Opportunities Associated with Targeted Cancer Therapies
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Codeveloping Targeted Therapies and Diagnostics: What's in it for Me?
Molecular Diagnostics in Cancer Testing
Molecular Diagnostics - Global Strategic Business Report
|
|
|
|
